Praxismanual Strahlentherapie:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | German |
| Veröffentlicht: |
Berlin
Springer
[2018]
|
| Ausgabe: | 2., vollständig überarbeitete und aktualisierte Auflage |
| Schlagworte: | |
| Online-Zugang: | Inhaltstext http://www.springer.com/ Inhaltsverzeichnis |
| Beschreibung: | XXXI, 497 Seiten 41 Illustrationen, 101 Diagramme |
| ISBN: | 9783662565766 3662565765 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV045030701 | ||
| 003 | DE-604 | ||
| 005 | 20190326 | ||
| 007 | t | ||
| 008 | 180620s2018 a||| |||| 00||| ger d | ||
| 015 | |a 18,N11 |2 dnb | ||
| 016 | 7 | |a 1153787067 |2 DE-101 | |
| 020 | |a 9783662565766 |c hbk. |9 978-3-662-56576-6 | ||
| 020 | |a 3662565765 |9 3-662-56576-5 | ||
| 024 | 3 | |a 9783662565766 | |
| 028 | 5 | 2 | |a Bestellnummer: 978-3-662-56576-6 |
| 028 | 5 | 2 | |a Bestellnummer: 86783905 |
| 035 | |a (OCoLC)1041786102 | ||
| 035 | |a (DE-599)DNB1153787067 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a ger | |
| 049 | |a DE-19 |a DE-578 |a DE-12 | ||
| 084 | |a WN 250 |2 nlm | ||
| 100 | 1 | |a Stöver, Imke |e Verfasser |0 (DE-588)140794832 |4 aut | |
| 245 | 1 | 0 | |a Praxismanual Strahlentherapie |c Imke Stöver, Petra Feyer ; mit einem Geleitwort von Prof. Dr. med. Wilfried Budach |
| 250 | |a 2., vollständig überarbeitete und aktualisierte Auflage | ||
| 264 | 1 | |a Berlin |b Springer |c [2018] | |
| 264 | 4 | |c © 2018 | |
| 300 | |a XXXI, 497 Seiten |b 41 Illustrationen, 101 Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Strahlentherapie |0 (DE-588)4057833-1 |2 gnd |9 rswk-swf |
| 653 | |a MJCL1 | ||
| 653 | |a Bestrahlung von Tumoren | ||
| 653 | |a Bronchialkarzinom | ||
| 653 | |a Hodentumore | ||
| 653 | |a Karzinom | ||
| 653 | |a Klassifikation | ||
| 653 | |a Lymphome | ||
| 653 | |a Mammakarzinom | ||
| 653 | |a Onkologie | ||
| 653 | |a Radioaktivität | ||
| 653 | |a Radioonkologie | ||
| 653 | |a Strahlentherapie | ||
| 653 | |a TNM-Klassifikation | ||
| 653 | |a Tumor | ||
| 653 | |a MJCL1 | ||
| 689 | 0 | 0 | |a Strahlentherapie |0 (DE-588)4057833-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Feyer, Petra |e Verfasser |0 (DE-588)11028920X |4 aut | |
| 700 | 1 | |a Budach, Wilfried |0 (DE-588)1152289926 |4 oth | |
| 710 | 2 | |a Springer-Verlag GmbH |0 (DE-588)1065168780 |4 pbl | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, ebk. |z 978-3-662-56577-3 |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=8e7a048c5e17494f87cd610b5ae35b42&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m X:MVB |u http://www.springer.com/ |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030422485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030422485 | ||
Datensatz im Suchindex
| _version_ | 1804178636546244608 |
|---|---|
| adam_text | INHALTSVERZEICHNIS
1 A LLG E M E IN E O N K O LO G IE
..............................................................................................
1
1.1
EPIDEMIOLOGIE.................................................................................................................
2
1.1.1
BEGRIFFE.............................................................................................................................
2
1.1.2 TYPISCHE RISIKOFAKTOREN FUER
TUMORERKRANKUNGEN...........................................................
2
1.1.3 EPIDEMIOLOGIE MALIGNER TUMORERKRANKUNGEN IN DEUTSCHLAND
......................................
2
1.1.4
PRAEVENTION........................................................................................................................
3
1.2 KLASSIFIKATION DES
ALLGEMEINZUSTANDS...........................................................................
3
1.3
TNM-KLASSIFIKATION.........................................................................................................
4
1.3.1 T:
PRIMAERTUMOR.................................................................................................................
4
1.3.2 N: REGIONAERE
LYMPHKNOTEN..............................................................................................
4
1.3.3 M:
FERNMETASTASEN..........................................................................................................
5
1.3.4 WEITERE
ANGABEN.............................................................................................................
5
1.3.5 HISTOPATHOLOGISCHES
GRADING..........................................................................................
6
1.4 BEURTEILUNG DES
THERAPIEERFOLGS...................................................................................
6
1.5
INDIKATIONSSTELLUNG.........................................................................................................
6
1.6 JURISTISCHE
ASPEKTE.........................................................................................................
7
1.6.1 AERZTLICHER
EINGRIFF.............................................................................................................
7
1.6.2
AUFKLAERUNG.......................................................................................................................
7
1.6.3 EINWILLIGUNGSUNFAEHIGKEIT DURCH FEHLENDE NATUERLICHE EINSICHTS- UND
URTEILSFAEHIGKEIT
....
8
1.6.4
PATIENTENRECHTEGESETZ....................................................................................................
9
1.6.5
STERBEHILFE........................................................................................................................
9
1.7 UNKONVENTIONELLE (KOMPLEMENTAERE)
THERAPIEN.......................................................... 10
1.7.1
ALLGEMEINES....................................................................................................................
10
1.7.2
MOTIVATION.......................................................................................................................
10
1.7.3
METHODEN........................................................................................................................
11
1.7.4
KRITIKPUNKTE....................................................................................................................
11
1.8 ONKOLOGISCHE
NACHSORGE...............................................................................................
11
1.8.1
ALLGEMEINES....................................................................................................................
11
1.8.2 RADIOONKOLOGISCHE
NACHSORGE.......................................................................................
12
2 U N ERW UENSCHTE S TRA H LE N TH E RA P IE FO LG E N
.............................................................
15
2.1
KLASSIFIKATIONEN..............................................................................................................
16
2.1.1 CTC-SKALA ZUR KLASSIFIKATION AKUTER
THERAPIEFOLGEN........................................................
16
2.1.2 CTCAE-KRITERIEN ZUR KLASSIFIKATION UNERWUENSCHTER EREIGNISSE
.......................................
16
2.1.3 RTOG/EORTC-SKALA ZUR KLASSIFIKATION CHRONISCHER NEBENWIRKUNGEN
............................
16
2.1.4 LENT-SOMA-SKALA ZUR KLASSIFIKATION CHRONISCHER
NEBENWIRKUNGEN............................... 16
2.2 STRAHLENFOLGEN IM ZEITLICHEN
VERLAUF.............................................................................
27
2.2.1
ALLGEMEINES....................................................................................................................
27
2.2.2 AKUTE
STRAHLENFOLGEN......................................................................................................
29
2.2.3 CHRONISCHE
STRAHLENFOLGEN.............................................................................................
29
2.2.4 CONSEQUENTIAL LATE
EFFECTS...............................................................................................
29
2.3 ALLGEMEINE UND ORGANSPEZIFISCHE STRAHLENFOLGEN
......................................................
29
2.3.1 ALLGEMEINE
STRAHLENFOLGEN..............................................................................................
30
2.3.2 ORGANSPEZIFISCHE
STRAHLENFOLGEN....................................................................................
30
2.4 SEKUNDAERE
NEOPLASIEN...................................................................................................
44
2.5 AKUTE
STRAHLENKRANKHEIT...............................................................................................
45
3
SUPPORTIVTHERAPIE
......................................................................................................
47
3.1
ALLGEMEINES....................................................................................................................
48
3.2 SYSTEMISCHE
PROBLEME...................................................................................................
48
3.2.1
FATIGUE.............................................................................................................................
48
3.2.2 MANGELERNAEHRUNG UND
KACHEXIE....................................................................................
48
3.2.3 NAUSEA UND
EMESIS.........................................................................................................
49
3.2.4
HYPERKALZIAEMIE................................................................................................................
51
3.2.5
HYPONATRIAEMIE.................................................................................................................
52
3.2.6 THERAPIEBEDINGTE LEUKOPENIE, THROMBOPENIE UND
ANAEMIE......................................... 53
3.3
SCHMERZTHERAPIE.............................................................................................................
54
3.3.1
ALLGEMEINES.....................................................................................................................
54
3.3.2 MEDIKAMENTOESE SCHMERZTHERAPIE
......................................................
54
3.3.3 INVASIVE UND NICHT MEDIKAMENTOESE SCHMERZTHERAPIE
...................................................
62
3.4 PFLEGE BESTRAHLTER
HAUT..................................................................................................
64
3.4.1
PROPHYLAXE.......................................................................................................................
64
3.4.2 BEHANDLUNG VON HAUTREAKTIONEN
...................................................................................
65
3.5
ZNS..................................................................................................................................
65
3.5.1
SYMPTOMATIK...................................................................................................................
65
3.5.2
PROPHYLAXE.......................................................................................................................
66
3.5.3
THERAPIE...........................................................................................................................
66
3.6
LUNGE..............................................................................................................................
66
3.6.1
SYMPTOMATIK...................................................................................................................
66
3.6.2
PROPHYLAXE.......................................................................................................................
67
3.6.3
THERAPIE...........................................................................................................................
67
3.7
HERZ.................................................................................................................................
67
3.7.1
SYMPTOMATIK...................................................................................................................
67
3.7.2
PROPHYLAXE.......................................................................................................................
68
3.7.3
THERAPIE...........................................................................................................................
68
3.7.4 VORGEHEN BEI LIEGENDEM SCHRITTMACHER/IMPLANTIERBAREM DEFIBRILLATOR
.......................
68
3.8
GASTROINTESTINALTRAKT......................................................................................................
69
3.8.1
MUNDTROCKENHEIT.............................................................................................................
69
3.8.2 MUKOSITIS UND
STOMATITIS.................................................................................................
70
3.8.3
DYSPHAGIE.......................................................................................................................
71
3.8.4
OBSTIPATION......................................................................................................................
72
3.8.5
DIARRHOE............................................................................................................................
72
3.8.6 RADIOGENE
PROKTITIS.........................................................................................................
73
3.9 UROGENITALE
STRAHLENTHERAPIEFOLGEN.............................................................................
74
3.9.1 RADIOGENE
ZYSTITIS...........................................................................................................
74
3.9.2 RADIOGENE
VULVOVAGINITIS................................................................................................
74
3.9.3 RADIOGENE
KEIMZELLSCHAEDIGUNG.....................................................................................
74
4 M E D IKA M E N TOE SE T U M O RTH E RA P IE FUE R R A D IO O N K O LO G
E N .................................... 77
4.1
ALLGEMEINES....................................................................................................................
78
4.1.1 ALLGEMEINES ZUR ZYTOSTATISCHEN
CHEMOTHERAPIE............................................................
78
4.1.2 KOMBINIERTE RADIOCHEMOTHERAPIE
.................................................................................
78
4.2 KLASSISCHE
ZYTOSTATIKA....................................................................................................
79
4.2.1
SUBSTANZGRUPPEN...........................................................................................................
79
4.2.2 STRAHLENTHERAPEUTISCH RELEVANTE
ASPEKTE......................................................................
79
4.3 *NEUE
SUBSTANZEN ........................................................................................................
82
4.3.1
SUBSTANZGRUPPEN...........................................................................................................
83
4.3.2 STRAHLENTHERAPEUTISCH RELEVANTE
ASPEKTE......................................................................
83
4.4
HORMONTHERAPIE............................................................................................................
86
4.4.1
ALLGEMEINES....................................................................................................................
86
4.4.2 SUBSTANZEN DER ANTINEOPLASTISCHEN
HORMONTHERAPIE.................................................... 87
4.5
WACHSTUMSFAKTOREN.......................................................................................................
87
4.5.1
ERYTHROPOETIN..................................................................................................................
87
4.5.2
G-CSF..............................................................................................................................
89
4.6
BISPHOSPHONATE.............................................................................................................
89
5 G LIO M E
..........................................................................................................................
91
5.1
ALLGEMEINES....................................................................................................................
92
5.1.1
EPIDEMIOLOGIE.................................................................................................................
92
5.1.2
AETIOLOGIE/RISIKOFAKTOREN.................................................................................................
92
5.1.3
ANATOMIE.........................................................................................................................
92
5.1.4
HISTOLOGIE........................................................................................................................
92
5.1.5
AUSBREITUNG....................................................................................................................
94
5.1.6
DIAGNOSTIK.......................................................................................................................
94
5.1.7
KLASSIFIKATION...................................................................................................................
94
5.1.8 ALLGEMEINES ZUR
THERAPIE................................................................................................
94
5.1.9
NACHSORGE.......................................................................................................................
97
5.1.10
PROGNOSE.........................................................................................................................
98
5.2 WHO-GRAD
II....................................................................................................................
98
5.2.1 ASTROZYTOM
....................................................................................................................
98
5.2.2 OLIGODENDROGLIOM UND
OLIGOASTROZYTOM.......................................................................
99
5.3 WHO-GRAD
III...................................................................................................................
99
5.3.1 ANAPIASTISCHES
ASTROZYTOM............................................................................................
99
5.3.2 ANAPIASTISCHES OLIGODENDROGLIOM UND ANAPLASTISCHES OLIGOASTROZYTOM
.....................
100
5.3.3 GLIOMATOSIS
CEREBRI...........................................................................................................101
5.4 WHO-GRAD
IV....................................................................................................................101
5.4.1
GLIOBLASTOM......................................................................................................................101
6 H N O -TUM
OREN..............................................................................................................
103
6.1
ALLGEMEINES.....................................................................................................................104
6.1.1
EPIDEMIOLOGIE..................................................................................................................
104
6.1.2
AETIOLOGIE/RISIKOFAKTOREN..................................................................................................
104
6.1.3
ANATOMIE..........................................................................................................................104
6.1.4
HISTOLOGIE.........................................................................................................................104
6.1.5
AUSBREITUNG......................................................................................................................105
6.1.6
DIAGNOSTIK.........................................................................................................................105
6.1.7
STADIENEINTEILUNG.............................................................................................................106
6.1.8
THERAPIE............................................................................................................................106
6.1.9
NACHSORGE.........................................................................................................................113
6.1.10
PROGNOSE...........................................................................................................................
113
6.2
LIPPENKARZINOM................................................................................................................113
6.2.1
ANATOMIE..........................................................................................................................
113
6.2.2
AUSBREITUNG......................................................................................................................
113
6.2.3
THERAPIE............................................................................................................................114
6.3
ZUNGENKARZINOM.............................................................................................................
114
6.3.1
ANATOMIE..........................................................................................................................
114
6.3.2
AUSBREITUNG......................................................................................................................
114
6.3.3
THERAPIE............................................................................................................................114
6.4
MUNDBODENKARZINOM.....................................................................................................
115
6.4.1 ANATOMIE
............................
115
6.4.2
AUSBREITUNG......................................................................................................................
115
6.4.3
THERAPIE............................................................................................................................115
6.5
WANGENKARZINOM............................................................................................................
115
6.5.1
ANATOMIE..........................................................................................................................
115
6.5.2
AUSBREITUNG......................................................................................................................
115
6.5.3
THERAPIE............................................................................................................................115
6.6 GINGIVA-, ALVEOLARKAMM-, HARTER-GAUMEN-,
TRIGONUM-RETROMOLARE-KARZINOM
..........
116
6.6.1
HISTOLOGIE.........................................................................................................................
116
6.6.2
ANATOMIE..........................................................................................................................
116
6.6.3
AUSBREITUNG......................................................................................................................
116
6.6.4
THERAPIE............................................................................................................................116
6.7
OROPHARYNXKARZINOM.....................................................................................................
117
6.7.1
ANATOMIE..........................................................................................................................
117
6.7.2
AUSBREITUNG......................................................................................................................
117
6.7.3
THERAPIE............................................................................................................................118
6.8 NASEN- UND
NASENNEBENHOEHLENKARZINOM.....................................................................118
6.8.1
HISTOLOGIE.........................................................................................................................
118
6.8.2
ANATOMIE..........................................................................................................................
118
6.8.3
AUSBREITUNG......................................................................................................................
118
6.8.4
THERAPIE............................................................................................................................119
6.8.5
PROGNOSE...........................................................................................................................
119
6.9
NASOPHARYNXKARZINOM....................................................................................................119
6.9.1
ALLGEMEINES......................................................................................................................
119
6.9.2
ANATOMIE..........................................................................................................................
118
6.9.3
AUSBREITUNG......................................................................................................................
119
6.9.4
THERAPIE............................................................................................................................119
6.10
HYPOPHARYNXKARZINOM...................................................................................................120
6.10.1
ANATOMIE..........................................................................................................................
120
6.10.2
AUSBREITUNG......................................................................................................................
120
6.10.3
THERAPIE............................................................................................................................120
6.10.4
PROGNOSE...........................................................................................................................
120
6.11
LARYNXKARZINOM..............................................................................................................
121
6.11.1
ALLGEMEINES.....................................................................................................................
121
6.11.2
ANATOMIE..........................................................................................................................121
6.11.3
AUSBREITUNG......................................................................................................................121
6.11.4
THERAPIE...........................................................................................................................
121
6.11.5
PROGNOSE..........................................................................................................................
123
6.12
SPEICHELDRUESENKARZINOM...............................................................................................123
6.12.1
ALLGEMEINES.....................................................................................................................
123
6.12.2
ANATOMIE.........................................................................................................................
123
6.12.3
HISTOLOGIE.........................................................................................................................123
6.12.4
AUSBREITUNG.....................................................................................................................
124
6.12.5
THERAPIE...........................................................................................................................
125
6.13 ZERVIKALES
CUP-SYNDROM...............................................................................................126
6.13.1
ALLGEMEINES.....................................................................................................................
126
6.13.2
HISTOLOGIE.........................................................................................................................126
6.13.3
AUSBREITUNG.....................................................................................................................126
6.13.4
DIAGNOSTIK........................................................................................................................126
6.13.5
THERAPIE...........................................................................................................................
127
6.13.6
PROGNOSE..........................................................................................................................
127
7 S C H ILD D RUE S E N K A RZ IN O M
.............................................................................................
129
7.1
EPIDEMIOLOGIE.................................................................................................................
130
7.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................130
7.3
ANATOMIE.........................................................................................................................130
7.4
HISTOLOGIE........................................................................................................................130
7.5
AUSBREITUNG.....................................................................................................................131
7.6
DIAGNOSTIK.......................................................................................................................
132
7.7
STADIENEINTEILUNG...........................................................................................................
132
7.8
THERAPIE..........................................................................................................................
132
7.8.1
ALLGEMEINES.....................................................................................................................
132
7.8.2
OPERATION.........................................................................................................................132
7.8.3
RADIOJODTHERAPIE.............................................................................................................
133
7.8.4
RADIOTHERAPIE...................................................................................................................
133
7.8.5
SYSTEMTHERAPIE.................................................................................................................135
7.9
NACHSORGE.......................................................................................................................
135
7.10
PROGNOSE..........................................................................................................................135
8 B RO N C H IA LK A RZ IN O M
.....................................................................................................
137
8.1
EPIDEMIOLOGIE.................................................................................................................
138
8.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................138
8.3
ANATOMIE.........................................................................................................................138
8.4
HISTOLOGIE........................................................................................................................
139
8.5
AUSBREITUNG.....................................................................................................................139
8.6
DIAGNOSTIK.......................................................................................................................
140
8.7 STADIENEINTEILUNG............
.
..............................................................................................
141
8.8
THERAPIE...........................................................................................................................
142
8.8.1
ALLGEMEINES......................................................................................................................
142
8.8.2 THERAPIE DES NICHTKLEINZELLIGEN BRONCHIALKARZINOMS
(NSCLC).........................................143
8.8.3 THERAPIE DES KLEINZELLIGEN BRONCHIALKARZINOMS (SCLC)
...................................................
146
8.9
NACHSORGE........................................................................................................................148
8.10
PROGNOSE..........................................................................................................................
148
9 P LE U RA M E S O TH E LIO M
....................................................................................................149
9.1
EPIDEMIOLOGIE..................................................................................................................150
9.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
150
9.3
ANATOMIE.........................................................................................................................
150
9.4
HISTOLOGIE.........................................................................................................................150
9.5
AUSBREITUNG.....................................................................................................................
150
9.6
DIAGNOSTIK........................................................................................................................151
9.7
STADIENEINTEILUNG............................................................................................................
151
9.8
THERAPIE...........................................................................................................................
151
9.8.1
ALLGEMEINES......................................................................................................................
151
9.8.2
OPERATION.........................................................................................................................
151
9.8.3
RADIOTHERAPIE....................................................................................................................151
9.8.4
SYSTEMTHERAPIE.................................................................................................................
153
9.9
NACHSORGE........................................................................................................................153
9.10
PROGNOSE..........................................................................................................................
153
10 T H Y M O M /T H Y M U S K A RZ IN O M
......................................................................................
155
10.1
EPIDEMIOLOGIE..................................................................................................................156
10.2
AETIOLOGIE/RISIKOFAKTOREN.................................................................................................
156
10.3
ANATOMIE.........................................................................................................................
156
10.4
HISTOLOGIE.........................................................................................................................
156
10.5
AUSBREITUNG......................................................................................................................156
10.6
DIAGNOSTIK........................................................................................................................157
10.7
STADIENEINTEILUNG............................................................................................................
157
10.8
THERAPIE...........................................................................................................................
157
10.8.1
ALLGEMEINES......................................................................................................................
157
10.8.2
OPERATION.........................................................................................................................
158
10.8.3
RADIOTHERAPIE....................................................................................................................158
10.8.4
CHEMOTHERAPIE.................................................................................................................
159
10.9
NACHSORGE........................................................................................................................159
10.10
PROGNOSE..........................................................................................................................
160
11 M A M M A K A RZ IN O M
.........................................................................................................161
11.1
EPIDEMIOLOGIE..................................................................................................................162
11.2
AETIOLOGIE/RISIKOFAKTOREN.................................................................................................
162
11.3
ANATOMIE.........................................................................................................................
162
11.4
HISTOLOGIE.........................................................................................................................162
11.5
AUSBREITUNG......................................................................................................................
165
11.5.1 LAGE DES
PRIMAERTUMORS....................................................................................................
165
11.5.2 LYMPHKNOTEN
BEFALL..........................................................................................................
165
11.5.3
FERNMETASTASIERUNG..........................................................................................................
165
11.6
DIAGNOSTIK.......................................................................................................................
165
11.7
STADIENEINTEILUNG...........................................................................................................
167
11.8
THERAPIE..........................................................................................................................
167
11.8.1
ALLGEMEINES......................................................................................................................167
11.8.2
OPERATION.........................................................................................................................167
11.8.3
RADIOTHERAPIE...................................................................................................................168
11.8.4
SYSTEMTHERAPIE................................................................................................................
172
11.9 NICHTINVASIVE
KARZINOME................................................................................................174
11.9.1 DUKTALES CARCINOMA IN SITU
(DCIS)...................................................................................
174
11.9.2 LOBULAERES CARCINOMA IN SITU (CLIS)
..................................................................................
175
11.10 LOKALES UND LOKOREGIONAERES
REZIDIV..............................................................................175
11.10.1
ALLGEMEINES.....................................................................................................................
175
11.10.2
THERAPIE...........................................................................................................................
176
11.11
SONDERSITUATIONEN..........................................................................................................176
11.11.1 INFLAMMATORISCHES
KARZINOM...........................................................................................176
11.11.2 MAMMAKARZINOM IN SCHWANGERSCHAFT UND
STILLZEIT........................................................177
11.11.3 MAMMAKARZINOM DES MANNES
........................................................................................
177
11.11.4 CYSTOSARCOMA
PHYLLOIDES..................................................................................................178
11.12
NACHSORGE.......................................................................................................................
178
11.13
PROGNOSE..........................................................................................................................178
12 OE SO P H A G U SKA RZIN O M
.................................................................................................
179
12.1
EPIDEMIOLOGIE.................................................................................................................
180
12.2 AETIOLOGIE/RISIKOFAKTOREN
...............................................................................................
180
12.3
ANATOMIE.........................................................................................................................180
12.4
HISTOLOGIE........................................................................................................................181
12.5
AUSBREITUNG.....................................................................................................................183
12.6
DIAGNOSTIK.......................................................................................................................
183
12.7
STADIENEINTEILUNG...........................................................................................................
184
12.8
THERAPIE..........................................................................................................................
184
12.8.1
ALLGEMEINES.....................................................................................................................184
12.8.2
OPERATION.........................................................................................................................184
12.8.3
RADIOTHERAPIE...................................................................................................................
185
12.8.4
SYSTEMTHERAPIE................................................................................................................
187
12.9
NACHSORGE.......................................................................................................................
187
12.10
PROGNOSE..........................................................................................................................188
13 M A G E N K A RZ IN O M
..........................................................................................................189
13.1
EPIDEMIOLOGIE.................................................................................................................190
13.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
190
13.3
ANATOMIE.........................................................................................................................190
13.4
HISTOLOGIE........................................................................................................................192
13.5
AUSBREITUNG.....................................................................................................................192
13.6
DIAGNOSTIK.......................................................................................................................
192
13.7
STADIENEINTEILUNG...........................................................................................................
192
13.8
THERAPIE..........................................................................................................................
193
13.8.1
ALLGEMEINES.....................................................................................................................193
13.8.2
OPERATION.........................................................................................................................
193
13.8.3
RADIOTHERAPIE...................................................................................................................193
13.8.4
SYSTEMTHERAPIE.................................................................................................................195
13.9
NACHSORGE........................................................................................................................195
13.10
PROGNOSE..........................................................................................................................
196
14 R E K TU M K A RZ IN O M
.........................................................................................................197
14.1
EPIDEMIOLOGIE..................................................................................................................198
14.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................198
14.3
ANATOMIE.........................................................................................................................
198
14.4
HISTOLOGIE.........................................................................................................................198
14.5
AUSBREITUNG.....................................................................................................................200
14.6
DIAGNOSTIK.......................................................................................................................
201
14.7
STADIENEINTEILUNG............................................................................................................201
14.8
THERAPIE...........................................................................................................................201
14.8.1
ALLGEMEINES......................................................................................................................201
14.8.2
OPERATION.........................................................................................................................202
14.8.3
RADIOTHERAPIE...................................................................................
202
14.8.4
SYSTEMTHERAPIE................................................................................................................
204
14.9
REZIDIV.............................................................................................................................
205
14.10
NACHSORGE.......................................................................................................................
205
14.11
PROGNOSE..........................................................................................................................205
15 A N A LKA N A L- U ND A N A LRA N D -K A RZ IN O M
.....................................................................207
15.1
EPIDEMIOLOGIE.................................................................................................................
208
15.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
208
15.3
ANATOMIE.........................................................................................................................
208
15.4
HISTOLOGIE........................................................................................................................
208
15.5
AUSBREITUNG.....................................................................................................................209
15.6
DIAGNOSTIK.......................................................................................................................
209
15.7
STADIENEINTEILUNG............................................................................................................209
15.8
THERAPIE...........................................................................................................................209
15.8.1
ALLGEMEINES......................................................................................................................209
15.8.2
OPERATION.........................................................................................................................
210
15.8.3
RADIOTHERAPIE...................................................................................................................
210
15.8.4
SYSTEMTHERAPIE................................................................................................................
211
15.9
NACHSORGE.......................................................................................................................
211
15.10
PROGNOSE..........................................................................................................................212
16 P A N KRE A SKA RZIN O M
......................................................................................................213
16.1
EPIDEMIOLOGIE..................................................................................................................214
16.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................214
16.3
ANATOMIE.........................................................................................................................
214
16.4
HISTOLOGIE........................................................................................................................
215
16.5
AUSBREITUNG.....................................................................................................................215
16.6
DIAGNOSTIK.......................................................................................................................
215
16.7
STADIENEINTEILUNG............................................................................................................216
16.8
THERAPIE..........................................................................................................................
216
16.8.1
ALLGEMEINES.....................................................................................................................
216
16.8.2
OPERATION.........................................................................................................................216
16.8.3
RADIOTHERAPIE...................................................................................................................217
16.8.4
SYSTEMTHERAPIE................................................................................................................
218
16.9
NACHSORGE.......................................................................................................................219
16.10
PROGNOSE.........................................................................................................................
219
17 H E P A TO ZE LLU LAE RE S K A RZ IN O M
.....................................................................................221
17.1
EPIDEMIOLOGIE.................................................................................................................
222
17.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
222
17.3
ANATOMIE.........................................................................................................................222
17.4
HISTOLOGIE........................................................................................................................222
17.5
AUSBREITUNG....................................................................................................................
222
17.6
DIAGNOSTIK.......................................................................................................................224
17.7
DIFFERENZIALDIAGNOSTIK...................................................................................................
224
17.8
STADIENEINTEILUNG...........................................................................................................
224
17.9
THERAPIE..........................................................................................................................
224
17.9.1
ALLGEMEINES.....................................................................................................................
224
17.9.2
OPERATION.........................................................................................................................225
17.9.3
RADIOTHERAPIE...................................................................................................................225
17.9.4 WEITERE LOKAL ABLATIVE
VERFAHREN.....................................................................................
225
17.9.5
SYSTEMTHERAPIE................................................................................................................
226
17.10
NACHSORGE.......................................................................................................................226
17.11
PROGNOSE.........................................................................................................................
226
18 TUM OREN D E R IN TRA - U N D E XTRA H E P A TISCH E N G ALLENW EGE,
CH O LA N G IO Z E LLU LAE RE S K A RZ IN O M
................................................................................227
18.1
EPIDEMIOLOGIE.................................................................................................................
228
18.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
228
18.3
ANATOMIE.........................................................................................................................228
18.4
HISTOLOGIE........................................................................................................................229
18.5
AUSBREITUNG....................................................................................................................
229
18.6
DIAGNOSTIK.......................................................................................................................229
18.7
STADIENEINTEILUNG...........................................................................................................
230
18.8
THERAPIE..........................................................................................................................
230
18.8.1
ALLGEMEINES.....................................................................................................................
230
18.8.2
OPERATION.........................................................................................................................230
18.8.3
RADIOTHERAPIE...................................................................................................................230
18.8.4
SYSTEMTHERAPIE................................................................................................................
231
18.8.5
SONSTIGES.........................................................................................................................
232
18.9
NACHSORGE.......................................................................................................................
232
18.10
PROGNOSE.........................................................................................................................
232
19 P RO S TA TA K A RZ IN O M
......................................................................................................233
19.1
EPIDEMIOLOGIE.................................................................................................................
234
19.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................234
19.3
ANATOMIE.........................................................................................................................
234
19.4
HISTOLOGIE........................................................................................................................
235
19.5
AUSBREITUNG.....................................................................................................................
235
19.6
DIAGNOSTIK........................................................................................................................237
19.7
STADIENEINTEILUNG............................................................................................................238
19.8
THERAPIE..........................................................................................................................238
19.8.1
ALLGEMEINES......................................................................................................................238
19.8.2 OPERATION
......................
239
19.8.3 PERKUTANE
RADIOTHERAPIE.................................................................................................
240
19.8.4 BRACHYTHERAPIE
...................................
241
19.8.5
SYSTEMTHERAPIE.................................................................................................................242
19.9
KASTRATIONSRESISTENZ........................................................................................................243
19.10
REZIDIV.............................................................................................................................
244
19.11
NACHSORGE........................................................................................................................244
19.12
PROGNOSE..........................................................................................................................
245
20 H O D E N TU M O RE N
............................................................................................................247
20.1
EPIDEMIOLOGIE..................................................................................................................248
20.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................
248
20.3
ANATOMIE.........................................................................................................................
248
20.4
HISTOLOGIE........................................................................................................................
249
20.5
AUSBREITUNG.....................................................................................................................
249
20.6
DIAGNOSTIK........................................................................................................................249
20.7
STADIENEINTEILUNG............................................................................................................249
20.8 THERAPIE DER GONADALEN
SEMINOME...............................................................................250
20.8.1
ALLGEMEINES......................................................................................................................250
20.8.2
OPERATION.........................................................................................................................
250
20.8.3
RADIOTHERAPIE...................................................................................................................
250
20.8.4
SYSTEMTHERAPIE.................................................................................................................252
20.9
NACHSORGE........................................................................................................................252
20.10
PROGNOSE..........................................................................................................................
252
21 P E N IS K A RZ IN O M
.............................................................................................................253
21.1
EPIDEMIOLOGIE..................................................................................................................254
21.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................
254
21.3
ANATOMIE.........................................................................................................................
254
21.4
HISTOLOGIE........................................................................................................................
255
21.5
AUSBREITUNG.....................................................................................................................
255
21.6
DIAGNOSTIK........................................................................................................................255
21.7
STADIENEINTEILUNG............................................................................................................255
21.8
THERAPIE...........................................................................................................................256
21.8.1
ALLGEMEINES......................................................................................................................256
21.8.2
OPERATION.........................................................................................................................
256
21.8.3
RADIOTHERAPIE...................................................................................................................
256
21.8.4
CHEMOTHERAPIE.................................................................................................................
258
21.9
NACHSORGE........................................................................................................................258
21.10
PROGNOSE..........................................................................................................................
258
22 E N D O M E TRIU M K A RZ IN O M
............................................................................................259
22.1
EPIDEMIOLOGIE.................................................................................................................260
22.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
260
22.3
ANATOMIE........................................................................................................................
260
22.4
HISTOLOGIE.......................................................................................................................
260
22.5
AUSBREITUNG....................................................................................................................
261
22.6
DIAGNOSTIK.......................................................................................................................262
22.7
STADIENEINTEILUNG...........................................................................................................262
22.8
THERAPIE..........................................................................................................................262
22.8.1
ALLGEMEINES.....................................................................................................................
262
22.8.2
OPERATION........................................................................................................................
264
22.8.3
RADIOTHERAPIE..................................................................................................................
264
22.8.4
CHEMOTHERAPIE................................................................................................................
266
22.8.5
HORMONTHERAPIE.............................................................................................................
267
22.9
REZIDIV............................................................................................................................
267
22.10
NACHSORGE.......................................................................................................................267
22.11
PROGNOSE.........................................................................................................................
267
22.12 SONDERFORM: KARZINOSARKOM (MALIGNER MUELLERSCHER MISCHTUMOR)
.............................
268
22.12.1
ALLGEMEINES.....................................................................................................................268
22.12.2
THERAPIE...........................................................................................................................268
22.12.3
PROGNOSE..........................................................................................................................
268
23 Z E RV IX K A RZ IN O M
..........................................................................................................
269
23.1
EPIDEMIOLOGIE.................................................................................................................270
23.2
AETIOLOGIE/RISIKOFAKTOREN...............................................................................................
270
23.3
ANATOMIE........................................................................................................................
270
23.4
HISTOLOGIE.......................................................................................................................
270
23.5
AUSBREITUNG....................................................................................................................
271
23.6
DIAGNOSTIK.......................................................................................................................272
23.7
STADIENEINTEILUNG...........................................................................................................
272
23.8
THERAPIE..........................................................................................................................
272
23.8.1
ALLGEMEINES.....................................................................................................................
272
23.8.2
OPERATION........................................................................................................................
273
23.8.3
RADIOTHERAPIE...................................................................................................................274
23.8.4
SYSTEMTHERAPIE................................................................................................................
277
23.9 ZERVIXKARZINOM IN DER
SCHWANGERSCHAFT.......................................................................277
23.10
REZIDIV.............................................................................................................................277
23.11
NACHSORGE.......................................................................................................................278
23.12
PROGNOSE.........................................................................................................................
278
24 V A G IN A LK A RZ IN O M
........................................................................................................279
24.1
EPIDEMIOLOGIE.................................................................................................................
280
24.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................280
24.3
ANATOMIE.........................................................................................................................280
24.4
HISTOLOGIE........................................................................................................................
281
24.5
AUSBREITUNG.....................................................................................................................281
24.6
DIAGNOSTIK.......................................................................................................................
281
24.7
STADIENEINTEILUNG............................................................................................................282
24.8
THERAPIE...........................................................................................................................282
24.8.1
ALLGEMEINES......................................................................................................................282
24.8.2
OPERATION.........................................................................................................................
282
24.8.3
RADIOTHERAPIE...................................................................................................................
282
24.8.4
CHEMOTHERAPIE.................................................................................................................284
24.9
REZIDIV.............................................................................................................................
285
24.10
NACHSORGE........................................................................................................................285
24.11
PROGNOSE..........................................................................................................................
285
25 V U LV A K A RZ IN O M
.............................................................................................................287
25.1
EPIDEMIOLOGIE..................................................................................................................288
25.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................
288
25.3
ANATOMIE.........................................................................................................................
288
25.4
HISTOLOGIE........................................................................................................................
288
25.5
AUSBREITUNG.....................................................................................................................289
25.6
DIAGNOSTIK.......................................................................................................................
289
25.7
STADIENEINTEILUNG............................................................................................................289
25.8
THERAPIE...........................................................................................................................290
25.8.1
ALLGEMEINES......................................................................................................................290
25.8.2
OPERATION.........................................................................................................................
290
25.8.3
RADIOTHERAPIE...................................................................................................................
291
25.8.4
CHEMOTHERAPIEE..............................................................................................................
293
25.9
REZIDIV.............................................................................................................................
293
25.10
NACHSORGE........................................................................................................................294
25.11
PROGNOSE..........................................................................................................................
294
26 N IE RE N Z E LLK A RZ IN O M
...................................................................................................
295
26.1
EPIDEMIOLOGIE..................................................................................................................296
26.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................
296
26.3
ANATOMIE.........................................................................................................................
296
26.4
HISTOLOGIE........................................................................................................................
297
26.5
AUSBREITUNG.....................................................................................................................297
26.6
DIAGNOSTIK.......................................................................................................................
297
26.7
STADIENEINTEILUNG............................................................................................................297
26.8
THERAPIE...........................................................................................................................297
26.8.1
ALLGEMEINES......................................................................................................................297
26.8.2
OPERATION.........................................................................................................................
297
26.8.3
RADIOTHERAPIE...................................................................................................................
298
26.8.4
SYSTEMTHERAPIE.................................................................................................................299
26.9
NACHSORGE........................................................................................................................299
26.10
PROGNOSE..........................................................................................................................
299
27 N IERENBECKEN- UND U RE TE RK A RZ IN O M
.....................................................................301
27.1
EPIDEMIOLOGIE..................................................................................................................302
27.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................
302
27.3
ANATOMIE.........................................................................................................................
302
27.4
HISTOLOGIE........................................................................................................................302
27.5
AUSBREITUNG....................................................................................................................
302
27.6
DIAGNOSTIK.......................................................................................................................
302
27.7
STADIENEINTEILUNG...........................................................................................................
302
27.8
THERAPIE..........................................................................................................................
303
27.8.1
OPERATION.........................................................................................................................303
27.8.2
RADIOTHERAPIE...................................................................................................................303
27.8.3
SYSTEMTHERAPIE................................................................................................................
304
27.9
NACHSORGE.......................................................................................................................
304
27.10
PROGNOSE.........................................................................................................................
305
28 H A RN B LA S E N K A RZ IN O M
.................................................................................................307
28.1
EPIDEMIOLOGIE.................................................................................................................
308
28.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................308
28.3
ANATOMIE.........................................................................................................................308
28.4
HISTOLOGIE........................................................................................................................308
28.5
AUSBREITUNG....................................................................................................................
308
28.6
DIAGNOSTIK.......................................................................................................................309
28.7
STADIENEINTEILUNG...........................................................................................................
309
28.8
THERAPIE..........................................................................................................................
309
28.8.1
ALLGEMEINES.....................................................................................................................
309
28.8.2
OPERATION.........................................................................................................................310
28.8.3
RADIOTHERAPIE...................................................................................................................310
28.8.4
SYSTEMTHERAPIE................................................................................................................
311
28.8.5 LOKALE
IMMUNTHERAPIE.....................................................................................................312
28.9
NACHSORGE.......................................................................................................................
312
28.10
PROGNOSE.........................................................................................................................
313
29 H O D G K IN -L Y M P H O M
....................................................................................................315
29.1
EPIDEMIOLOGIE.................................................................................................................
316
29.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................316
29.3
HISTOLOGIE........................................................................................................................316
29.4
AUSBREITUNG....................................................................................................................
316
29.5
DIAGNOSTIK.......................................................................................................................316
29.6
KLASSIFIKATIONEN...............................................................................................................317
29.6.1 ANN ARBOR
KLASSIFIKATION..................................................................................................
317
29.6.2
LYMPHKNOTENREGIONEN....................................................................................................317
29.6.3
PROGNOSEGRUPPEN............................................................................................................
318
29.7
THERAPIE..........................................................................................................................
321
29.7.1
ALLGEMEINES.....................................................................................................................
321
29.7.2 STADIENADAPTIERTE
THERAPIEEMPFEHLUNGEN.....................................................................
321
29.7.3
RADIOTHERAPIE...................................................................................................................322
29.7.4
SYSTEMTHERAPIE................................................................................................................
324
29.7.5 THERAPIEBEDINGTE
TOXIZITAET..............................................................................................324
29.8
REZIDIV.............................................................................................................................325
29.9 NACHSORGE
..................
325
29.10
PROGNOSE.........................................................................................................................
325
30 N O N -H O D G K IN -L Y M P H O M E
.........................................................................................327
30.1
ALLGEMEINES.....................................................................................................................
328
30.1.1
EPIDEMIOLOGIE...................................................................................................................328
30.1.2
AETIOLOGIE/RISIKOFAKTOREN..................................................................................................328
30.1.3
HISTOLOGIE.........................................................................................................................
328
30.1.4
AUSBREITUNG......................................................................................................................
330
30.1.5
DIAGNOSTIK........................................................................................................................
330
30.1.6
STADIENEINTEILUNG.............................................................................................................331
30.1.7
THERAPIE............................................................................................................................331
30.2 SPEZIELLE
KRANKHEITSBILDER.............................................................................................336
30.2.1 FOLLIKULAERES LYMPHOM GRAD
L/LL.........................................................................................336
30.2.2 FOLLIKULAERES LYMPHOM GRAD
III..........................................................................................337
30.2.3 NODALES
MARGINALZONENLYMPHOM....................................................................................337
30.2.4
MANTELZELLLYMPHOM.........................................................................................................
337
30.2.5 AGGRESSIVE
LYMPHOME.....................................................................................................
338
30.2.6 PRIMAER EXTRANODALE
LYMPHOME.......................................................................................
338
30.2.7 MULTIPLES
MYELOM.............................................................................................................345
30.2.8 LYMPHOPLASMOZYTISCHES LYMPHOM
(IMMUNOZYTOM).....................................................348
30.2.9 CHRONISCHE LYMPHATISCHE LEUKAEMIE
(CLL).......................................................................
348
31 S A RK O M E
........................................................................................................................
351
31.1
EPIDEMIOLOGIE..................................................................................................................352
31.2
AETIOLOGIE/RISIKOFAKTOREN................................................................................................
352
31.3
ANATOMIE.........................................................................................................................
352
31.4
HISTOLOGIE........................................................................................................................
352
31.5
AUSBREITUNG.....................................................................................................................
352
31.6
DIAGNOSTIK........................................................................................................................353
31.7
STADIENEINTEILUNG............................................................................................................353
31.8
THERAPIE...........................................................................................................................
353
31.8.1
ALLGEMEINES......................................................................................................................353
31.8.2
OPERATION.........................................................................................................................
354
31.8.3
RADIOTHERAPIE..................................................................................................................
354
31.8.4
CHEMOTHERAPIE.................................................................................................................
356
31.9
REZIDIV..............................................................................................................................357
31.10
NACHSORGE........................................................................................................................357
31.11
PROGNOSE..........................................................................................................................
357
31.12
SONDERFAELLE.......................................................................................................................358
31.12.1 GASTROINTESTINALE STROMATUMOREN
(GIST).........................................................................358
31.12.2
UTERUSSARKOME.................................................................................................................
358
31.12.3
KAPOSI-SARKOM..................................................................................................................360
32 H A U TTU M O RE N
................................................................................................................
363
32.1
ALLGEMEINES.....................................................................................................................
364
32.1.1
AETIOLOGIE/RISIKOFAKTOREN.................................................................................................
364
32.1.2 THERAPIEKONZEPTE UND
KLASSIFIKATION.............................................................................
364
32.2
PRAEKANZEROESEN.................................................................................................................
364
32.2.1 AKTINISCHE
KERATOSE.........................................................................................................364
32.2.2 M.
BOWEN.........................................................................................................................
365
32.2.3 LENTIGO
MALIGNA...............................................................................................................365
32.3
BASALIOM..........................................................................................................................
365
32.3.1
ALLGEMEINES.....................................................................................................................
365
32.3.2
THERAPIE...........................................................................................................................
366
32.3.3
PROGNOSE..........................................................................................................................
367
32.4
PLATTENEPITHELKARZINOM.................................................................................................
367
32.4.1
ALLGEMEINES.....................................................................................................................
367
32.4.2
THERAPIE...........................................................................................................................
367
32.4.3
PROGNOSE..........................................................................................................................
368
32.5 MALIGNES
MELANOM..........................................................................................................368
32.5.1
ALLGEMEINES.....................................................................................................................
368
32.5.2
STADIENEINTEILUNG............................................................................................................
369
32.5.3
THERAPIE...........................................................................................................................
369
32.5.4
PROGNOSE..........................................................................................................................
370
32.6
MERKELZELLKARZINOM........................................................................................................
371
32.6.1
ALLGEMEINES.....................................................................................................................
371
32.6.2
THERAPIE...........................................................................................................................
371
32.6.3
PROGNOSE..........................................................................................................................
372
33
NEUROENDOKRINE TUMOREN/NEOPLASIEN (NET/NEN)
...........................................373
33.1
ALLGEMEINES....................................................................................................................
374
33.1.1
EPIDEMIOLOGIE..................................................................................................................374
33.1.2
AETIOLOGIE/RISIKOFAKTOREN..................................................................................................
374
33.1.3
HISTOLOGIE.........................................................................................................................374
33.1.4
KLINIK................................................................................................................................
374
33.1.5
DIAGNOSTIK........................................................................................................................375
33.1.6
KLASSIFIKATION/STADIENEINTEILUNG......................................................................................375
33.2 SPEZIELLE
KRANKHEITSBILDER............................................................................................
375
33.2.1 NEUROENDOKRINE TUMOREN/NEOPLASIEN DER LUNGE
..........................................................
375
33.2.2 NEUROENDOKRINE TUMOREN/NEOPLASIEN DES
GASTROINTESTINALTRAKTES................................377
33.2.3 NEUROENDOKRINES KARZINOM DER HAUT
.............................................................................
378
34
PAEDIATRISCHE RADIOONKOLOGIE
..................................................................................379
34.1
ALLGEMEINES....................................................................................................................
380
34.2 SPEZIELLE
KRANKHEITSBILDER.............................................................................................
381
34.2.1
MEDULLOBLASTOM...............................................................................................................381
34.2.2
EPENDYMOM....................................................................................................................
382
34.2.3
ASTROZYTOM......................................................................................................................
383
34.2.4
KEIMZELLTUMOR.................................................................................................................
384
34.2.5
RETINOBLASTOM.................................................................................................................
385
34.2.6
OSTEOSARKOM....................................................................................................................386
34.2.7
EWING-SARKOM..................................................................................................................387
34.2.8
WEICHTEILSARKOM...............................................................................................................388
34.2.9
NEUROBLASTOM..................................................................................................................389
34.2.10 NEPHROBLASTOM (WILMS-TUMOR)
.......................................................................................
390
34.2.11
LEUKAEMIE.........................................................................................................................
391
34.2.12
HODGKIN-LYMPHOM..........................................................................................................
392
34.2.13
NON-HODGKIN-LYMPHOM..................................................................................................392
35 P A LLIA TIV E R A D IO TH E RA P IE
...........................................................................................
395
35.1
ALLGEMEINES.....................................................................................................................
396
35.2
KNOCHENMETASTASEN........................................................................................................396
35.2.1
ALLGEMEINES......................................................................................................................
396
35.2.2
KLINIK.................................................................................................................................396
35.2.3
DIAGNOSTIK........................................................................................................................
397
35.2.4
THERAPIE............................................................................................................................397
35.2.5
PROGNOSE...........................................................................................................................399
35.3
HIRNMETASTASEN..............................................................................................................
399
35.3.1
ALLGEMEINES......................................................................................................................399
35.3.2
KLINIK.................................................................................................................................400
35.3.3
DIAGNOSTIK........................................................................................................................
400
35.3.4
THERAPIE............................................................................................................................400
35.3.5
PROGNOSE...........................................................................................................................402
35.4
SONSTIGES........................................................................................................................402
35.4.1 MENINGEOSIS CARCINOMATOSA, LEPTOMENIGEALE AUSSAAT VON
LYMPHOMEN UND
LEUKAEMIEN...........................................................................................402
35.4.2
LEBERMETASTASEN.............................................................................................................
403
35.4.3
SPLENOMEGALIE..................................................................................................................403
35.4.4 SCHMERZHAFTE WEICHTEILINFILTRATION DURCH INOPERABLES
TUMORWACHSTUM
.......................
404
35.4.5 LYMPHKNOTENMETASTASEN UND SONSTIGE
FERNMETASTASEN...............................................404
36 S TRA H LE N TH E RA P E U TIS C H E N O TFA LLS ITU A TIO N E N
....................................................... 405
36.1 OBERE
EINFLUSSSTAUUNG..................................................................................................
406
36.1.1
URSACHEN...........................................................................................................................406
36.1.2
KLINIK.................................................................................................................................406
36.1.3
DIAGNOSTIK........................................................................................................................
406
36.1.4
THERAPIE............................................................................................................................406
36.1.5
PROGNOSE...........................................................................................................................407
36.2 AKUTE SPINALE KOMPRESSION
..........................................................................................
407
36.2.1
URSACHEN...........................................................................................................................407
36.2.2
KLINIK.................................................................................................................................407
36.2.3
DIAGNOSTIK........................................................................................................................
407
36.2.4
THERAPIE............................................................................................................................408
36.2.5
PROGNOSE...........................................................................................................................408
36.3 AKUTE INTRAKRANIELLE
DRUCKSTEIGERUNG..........................................................................408
36.3.1
URSACHEN...........................................................................................................................408
36.3.2
KLINIK.................................................................................................................................408
36.3.3
DIAGNOSTIK........................................................................................................................
408
36.3.4
THERAPIE............................................................................................................................409
36.3.5
PROGNOSE...........................................................................................................................409
36.4
TUMORBLUTUNG................................................................................................................
409
36.4.1
DIAGNOSTIK........................................................................................................................
409
36.4.2
THERAPIE............................................................................................................................409
36.4.3
PROGNOSE...........................................................................................................................409
37 G U TA RTIG E E RK RA N K U N G E N
..........................................................................................411
37.1
ALLGEMEINES....................................................................................................................
413
37.2
MENINGEOM.....................................................................................................................
413
37.2.1
ALLGEMEINES.....................................................................................................................
413
37.2.2
THERAPIE...........................................................................................................................414
37.3
HYPOPHYSENADENOM......................................................................................................
414
37.3.1
ALLGEMEINES.....................................................................................................................
414
37.3.2
THERAPIE...........................................................................................................................415
37.4
KRANIOPHARYNGEOM.........................................................................................................415
37.4.1
ALLGEMEINES.....................................................................................................................
415
37.4.2
THERAPIE...........................................................................................................................415
37.5
AKUSTIKUSNEURINOM........................................................................................................416
37.5.1
ALLGEMEINES.....................................................................................................................
416
37.5.2
THERAPIE...........................................................................................................................416
37.6 JUVENILES
NASEN-RACHEN-FIBROM...................................................................................
417
37.6.1
ALLGEMEINES.....................................................................................................................
417
37.6.2
THERAPIE...........................................................................................................................417
37.7
CHORDOM.........................................................................................................................
417
37.7.1
ALLGEMEINES.....................................................................................................................
417
37.7.2
THERAPIE...........................................................................................................................417
37.8 GLOMUSTUMOR (NICHT CHROMAFFINES
PARAGANGLIOM).......................................................418
37.8.1
ALLGEMEINES.....................................................................................................................
418
37.8.2
THERAPIE...........................................................................................................................418
37.9 ARTERIOVENOESE MALFORMATION
(AVM)..............................................................................
418
37.9.1
ALLGEMEINES.....................................................................................................................
418
37.9.2
THERAPIE...........................................................................................................................419
37.10 ENDOKRINE ORBITOPATHIE
(EO).........................................................................................420
37.10.1
ALLGEMEINES.....................................................................................................................
420
37.10.2
THERAPIE...........................................................................................................................420
37.11 ALTERSABHAENGIGE
MAKULADEGENERATION.........................................................................
421
37.11.1
ALLGEMEINES.....................................................................................................................
421
37.11.2
THERAPIE...........................................................................................................................421
37.12
PTERYGIUM.......................................................................................................................
421
37.12.1
ALLGEMEINES.....................................................................................................................
421
37.12.2
THERAPIE...........................................................................................................................421
37.13 HAEMANGIOM DER
ADERHAUT.............................................................................................422
37.13.1
ALLGEMEINES.....................................................................................................................
422
37.13.2
THERAPIE...........................................................................................................................422
37.14 PSEUDOTUMOR
ORBITAE.....................................................................................................
422
37.14.1
ALLGEMEINES.....................................................................................................................
422
37.14.2
THERAPIE...........................................................................................................................423
37.15 DEGENERATIVE GELENKERKRANKUNGEN UND
INSERTIONSTENDINOPATHIEN..........................423
37.15.1
ALLGEMEINES.....................................................................................................................
423
37.15.2
THERAPIE...........................................................................................................................423
37.16
KELOID..............................................................................................................................
424
37.16.1
ALLGEMEINES.....................................................................................................................
424
37.16.2 THERAPIE
......................
424
37.17 M. DUPUYTREN UND M.
LEDDERHOSE.................................................................................
424
37.17.1
ALLGEMEINES......................................................................................................................424
37.17.2
THERAPIE............................................................................................................................425
37.18 INDURATIO PENIS
PLASTICA...................................................................................................425
37.18.1
ALLGEMEINES......................................................................................................................425
37.18.2
THERAPIE............................................................................................................................426
37.19
GYNAEKOMASTIE.................................................................................................................
427
37.19.1
ALLGEMEINES......................................................................................................................427
37.19.2
THERAPIE............................................................................................................................427
37.20 DESMOID (AGGRESSIVE
FIBROMATOSE)...............................................................................
427
37.20.1
ALLGEMEINES......................................................................................................................427
37.20.2
THERAPIE............................................................................................................................428
37.21 PIGMENTIERTE VILLONODULOESE
SYNOVITIS...........................................................................
428
37.21.1
ALLGEMEINES......................................................................................................................428
37.21.2
THERAPIEOPTIONEN............................................................................................................
428
37.22 VERTEBRALES
HAEMANGIOM.................................................................................................429
37.22.1
ALLGEMEINES......................................................................................................................429
37.22.2
THERAPIE...........................................................................................................................
429
37.23 ANEURYSMATISCHE
KNOCHENZYSTE....................................................................................
429
37.23.1
ALLGEMEINES......................................................................................................................429
37.23.2
THERAPIE............................................................................................................................429
37.24 HETEROTOPE OSSIFIKATIONEN
(HO)....................................................................................
430
37.24.1
ALLGEMEINES......................................................................................................................430
37.24.2
THERAPIE...........................................................................................................................
430
38
STRAHLENSCHUTZ
............................................................................................................
433
38.1
STRAHLENSCHUTZVERORDNUNG.............................................................................................434
38.1.1
ALLGEMEINES......................................................................................................................434
38.1.2
BEGRIFFSDEFINITIONEN.........................................................................................................
434
38.1.3 REGELUNGEN ZU TAETIGKEITEN IM RAHMEN ZIELGERICHTETER NUTZUNG
IONISIERENDER
STRAHLUNG..........................................................................................................................436
38.2 RICHTLINIE STRAHLENSCHUTZ IN DER
MEDIZIN.......................................................................440
38.2.1
ALLGEMEINES......................................................................................................................440
38.2.2 REGELUNGEN ZU ANFORDERUNGEN/VORAUSSETZUNGEN FUER DIE ANWENDUNG
RADIOAKTIVER
STOFFE UND IONISIERENDER STRAHLUNG IN DER
MEDIZIN..........................................................440
39
ICD-1
O-GM-KLASSIFIKATION
........................................................................................
445
39.1 BOESARTIGE
NEUBILDUNGEN................................................................................................446
39.2 STRAHLENTHERAPEUTISCH RELEVANTE NICHT-MALIGNE ERKRANKUNGEN
.................................
467
SERVICETEIL
GLOSSAR.............................................................................................................................
472
STICHWORTVERZEICHNIS.......................................................................................................491
|
| any_adam_object | 1 |
| author | Stöver, Imke Feyer, Petra |
| author_GND | (DE-588)140794832 (DE-588)11028920X (DE-588)1152289926 |
| author_facet | Stöver, Imke Feyer, Petra |
| author_role | aut aut |
| author_sort | Stöver, Imke |
| author_variant | i s is p f pf |
| building | Verbundindex |
| bvnumber | BV045030701 |
| ctrlnum | (OCoLC)1041786102 (DE-599)DNB1153787067 |
| edition | 2., vollständig überarbeitete und aktualisierte Auflage |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02465nam a2200661 c 4500</leader><controlfield tag="001">BV045030701</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190326 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">180620s2018 a||| |||| 00||| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">18,N11</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1153787067</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783662565766</subfield><subfield code="c">hbk.</subfield><subfield code="9">978-3-662-56576-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3662565765</subfield><subfield code="9">3-662-56576-5</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783662565766</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">Bestellnummer: 978-3-662-56576-6</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">Bestellnummer: 86783905</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1041786102</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1153787067</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-578</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WN 250</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stöver, Imke</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)140794832</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Praxismanual Strahlentherapie</subfield><subfield code="c">Imke Stöver, Petra Feyer ; mit einem Geleitwort von Prof. Dr. med. Wilfried Budach</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2., vollständig überarbeitete und aktualisierte Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin</subfield><subfield code="b">Springer</subfield><subfield code="c">[2018]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXXI, 497 Seiten</subfield><subfield code="b">41 Illustrationen, 101 Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Strahlentherapie</subfield><subfield code="0">(DE-588)4057833-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MJCL1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bestrahlung von Tumoren</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bronchialkarzinom</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hodentumore</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Karzinom</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Klassifikation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Lymphome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mammakarzinom</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Onkologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Radioaktivität</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Radioonkologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Strahlentherapie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TNM-Klassifikation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MJCL1</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Strahlentherapie</subfield><subfield code="0">(DE-588)4057833-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Feyer, Petra</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)11028920X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Budach, Wilfried</subfield><subfield code="0">(DE-588)1152289926</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Springer-Verlag GmbH</subfield><subfield code="0">(DE-588)1065168780</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, ebk.</subfield><subfield code="z">978-3-662-56577-3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=8e7a048c5e17494f87cd610b5ae35b42&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="u">http://www.springer.com/</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030422485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030422485</subfield></datafield></record></collection> |
| id | DE-604.BV045030701 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:07:07Z |
| institution | BVB |
| institution_GND | (DE-588)1065168780 |
| isbn | 9783662565766 3662565765 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030422485 |
| oclc_num | 1041786102 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-578 DE-12 |
| owner_facet | DE-19 DE-BY-UBM DE-578 DE-12 |
| physical | XXXI, 497 Seiten 41 Illustrationen, 101 Diagramme |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Springer |
| record_format | marc |
| spelling | Stöver, Imke Verfasser (DE-588)140794832 aut Praxismanual Strahlentherapie Imke Stöver, Petra Feyer ; mit einem Geleitwort von Prof. Dr. med. Wilfried Budach 2., vollständig überarbeitete und aktualisierte Auflage Berlin Springer [2018] © 2018 XXXI, 497 Seiten 41 Illustrationen, 101 Diagramme txt rdacontent n rdamedia nc rdacarrier Strahlentherapie (DE-588)4057833-1 gnd rswk-swf MJCL1 Bestrahlung von Tumoren Bronchialkarzinom Hodentumore Karzinom Klassifikation Lymphome Mammakarzinom Onkologie Radioaktivität Radioonkologie Strahlentherapie TNM-Klassifikation Tumor Strahlentherapie (DE-588)4057833-1 s DE-604 Feyer, Petra Verfasser (DE-588)11028920X aut Budach, Wilfried (DE-588)1152289926 oth Springer-Verlag GmbH (DE-588)1065168780 pbl Erscheint auch als Online-Ausgabe, ebk. 978-3-662-56577-3 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=8e7a048c5e17494f87cd610b5ae35b42&prov=M&dok_var=1&dok_ext=htm Inhaltstext X:MVB http://www.springer.com/ DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030422485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Stöver, Imke Feyer, Petra Praxismanual Strahlentherapie Strahlentherapie (DE-588)4057833-1 gnd |
| subject_GND | (DE-588)4057833-1 |
| title | Praxismanual Strahlentherapie |
| title_auth | Praxismanual Strahlentherapie |
| title_exact_search | Praxismanual Strahlentherapie |
| title_full | Praxismanual Strahlentherapie Imke Stöver, Petra Feyer ; mit einem Geleitwort von Prof. Dr. med. Wilfried Budach |
| title_fullStr | Praxismanual Strahlentherapie Imke Stöver, Petra Feyer ; mit einem Geleitwort von Prof. Dr. med. Wilfried Budach |
| title_full_unstemmed | Praxismanual Strahlentherapie Imke Stöver, Petra Feyer ; mit einem Geleitwort von Prof. Dr. med. Wilfried Budach |
| title_short | Praxismanual Strahlentherapie |
| title_sort | praxismanual strahlentherapie |
| topic | Strahlentherapie (DE-588)4057833-1 gnd |
| topic_facet | Strahlentherapie |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=8e7a048c5e17494f87cd610b5ae35b42&prov=M&dok_var=1&dok_ext=htm http://www.springer.com/ http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030422485&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT stoverimke praxismanualstrahlentherapie AT feyerpetra praxismanualstrahlentherapie AT budachwilfried praxismanualstrahlentherapie AT springerverlaggmbh praxismanualstrahlentherapie |